WILLIAM MAYO: Open Payments
NPI 1558817809 · CLEMSON, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,223 in 110 payments from 21 companies in 2025. Trend: 2023 $306 · 2024 $1,429 · 2025 $2,223
Food & beverage: $2,223
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 16 | $553 |
| ABBVIE INC. | 42 | $481 |
| Otsuka America Pharmaceutical, Inc. | 7 | $168 |
| GlaxoSmithKline, LLC. | 9 | $167 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $145 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $121 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $111 |
| Axsome Therapeutics, Inc. | 3 | $87 |
| PFIZER INC. | 4 | $85 |
| Novartis Pharmaceuticals Corporation | 3 | $47 |
Products named: VRAYLAR, REXULTI, TRELEGY ELLIPTA, BREZTRI, QULIPTA, Kerendia, AIRSUPRA, FARXIGA.
Industry payments across SC — which companies pay providers there.
